Proniosomes are novel vesicular carriers that provide improved drug encapsulation, low aggregation, prolonged retention of drug and hence increased bioavailability.
Recent proniosomes formulations are:
Terconazole- ocular fungal keratitis
Efinaconazole- topical fungal infections
Crisaborole- atopic dermatitis
Doxycycline- periodontal diseases
This suggests that soon we will have a new era of targeted and more efficient drug therapies.
informative.
Their ability to enhance drug stability, prolong retention, and improve bioavailability could transform treatments for various conditions.
Proniosomes are indeed an exciting step forward in drug delivery they bridge the stability of dry formulations with the efficiency of vesicular systems like niosomes. By minimising aggregation and controlling drug release, they not only improve bioavailability but also make treatments more precise and patient friendly. With recent applications spanning ocular, dermatological, and periodontal conditions, they point toward a future where therapies are more targeted, longer lasting, and require smaller doses reducing side effects while improving outcomes.
Informative!
Thanks for the information
Proniosomes sound like a big leap in drug delivery tech 
Targeted action, better stability, and higher bioavailability-all in one package. With recent formulations like terconazole for eye infections and doxycycline for gum disease, this could really change how we treat stubborn conditions.
Thanks for sharing.
Informative.Thanks for sharing.
That’s really interesting. Proniosomes seem to be opening doors for safer, targeted, and more effective drug delivery in different diseases.